FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016194112> ?p ?o ?g. }

• W2016194112 endingPage "1895" @default.
• W2016194112 startingPage "1886" @default.
• W2016194112 abstract "Exploration of the human melanoma cell-cycle pathway can lead to identification of new therapeutic targets. By gene set enrichment analysis, we identified the cell-cycle pathway and its member polo-like kinase 1 (Plk-1) to be significantly overexpressed in primary melanomas and in melanoma metastases. In vitro expression of Plk-1 was peaked at the G2/M phase of the cell cycle. Plk-1 knockdown/inhibition led to induction of apoptosis, which was caspase-3/8-dependent and p53-independent, and involved BID and Bcl-2 proteins. Comparative genomic hybridization/single-nucleotide polymorphism arrays showed no genetic alteration in the Plk-1 locus. Previous suggestions and significant enrichment of the mitogen-activated protein kinase (MAPK) signaling pathway pointed to potential regulation of Plk-1 by MAPK signaling. Inhibition of this pathway resulted in decreased Plk-1 expression as a consequence of G1 cell-cycle arrest rather than direct regulation of Plk-1. Inhibition of MAPK and Plk-1 had an additive effect on reduced cell viability. This study shows that in human melanoma, Plk-1 expression is dynamically regulated during the cell cycle, knockdown of Plk-1 leads to apoptotic cell death, and that a combination of Plk-1 and MAPK inhibition has an additive effect on melanoma cell viability. We conclude that combined inhibition of Plk-1 and MAPK could be a potentially attractive strategy in melanoma therapy. Exploration of the human melanoma cell-cycle pathway can lead to identification of new therapeutic targets. By gene set enrichment analysis, we identified the cell-cycle pathway and its member polo-like kinase 1 (Plk-1) to be significantly overexpressed in primary melanomas and in melanoma metastases. In vitro expression of Plk-1 was peaked at the G2/M phase of the cell cycle. Plk-1 knockdown/inhibition led to induction of apoptosis, which was caspase-3/8-dependent and p53-independent, and involved BID and Bcl-2 proteins. Comparative genomic hybridization/single-nucleotide polymorphism arrays showed no genetic alteration in the Plk-1 locus. Previous suggestions and significant enrichment of the mitogen-activated protein kinase (MAPK) signaling pathway pointed to potential regulation of Plk-1 by MAPK signaling. Inhibition of this pathway resulted in decreased Plk-1 expression as a consequence of G1 cell-cycle arrest rather than direct regulation of Plk-1. Inhibition of MAPK and Plk-1 had an additive effect on reduced cell viability. This study shows that in human melanoma, Plk-1 expression is dynamically regulated during the cell cycle, knockdown of Plk-1 leads to apoptotic cell death, and that a combination of Plk-1 and MAPK inhibition has an additive effect on melanoma cell viability. We conclude that combined inhibition of Plk-1 and MAPK could be a potentially attractive strategy in melanoma therapy. gene set enrichment analysis c-Jun N-terminal kinase mitogen-activated protein kinase mitogen-activated protein kinase kinase 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide phosphate-buffered saline propidium iodide polo-like kinase 1 small-interfering RNA western blot" @default.
• W2016194112 created "2016-06-24" @default.
• W2016194112 creator A5011094627 @default.
• W2016194112 creator A5032742387 @default.
• W2016194112 creator A5038704848 @default.
• W2016194112 creator A5043359083 @default.
• W2016194112 creator A5050880185 @default.
• W2016194112 creator A5054046984 @default.
• W2016194112 creator A5073284900 @default.
• W2016194112 creator A5080570964 @default.
• W2016194112 creator A5089220498 @default.
• W2016194112 creator A5090252753 @default.
• W2016194112 date "2011-09-01" @default.
• W2016194112 modified "2023-09-25" @default.
• W2016194112 title "Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma" @default.
• W2016194112 cites W1516211547 @default.
• W2016194112 cites W169077027 @default.
• W2016194112 cites W1864382350 @default.
• W2016194112 cites W1949238489 @default.
• W2016194112 cites W1965688832 @default.
• W2016194112 cites W1971947883 @default.
• W2016194112 cites W1982304115 @default.
• W2016194112 cites W1991605733 @default.
• W2016194112 cites W1993941887 @default.
• W2016194112 cites W2006401070 @default.
• W2016194112 cites W2014252192 @default.
• W2016194112 cites W2018155127 @default.
• W2016194112 cites W2020411912 @default.
• W2016194112 cites W2020516698 @default.
• W2016194112 cites W2021246859 @default.
• W2016194112 cites W2022892479 @default.
• W2016194112 cites W2024611245 @default.
• W2016194112 cites W2025540821 @default.
• W2016194112 cites W2035853571 @default.
• W2016194112 cites W2039568202 @default.
• W2016194112 cites W2041238848 @default.
• W2016194112 cites W2049835633 @default.
• W2016194112 cites W2051210198 @default.
• W2016194112 cites W2052298707 @default.
• W2016194112 cites W2055288483 @default.
• W2016194112 cites W2055501079 @default.
• W2016194112 cites W2066420625 @default.
• W2016194112 cites W2082087067 @default.
• W2016194112 cites W2092021778 @default.
• W2016194112 cites W2095280226 @default.
• W2016194112 cites W2105712639 @default.
• W2016194112 cites W2106543129 @default.
• W2016194112 cites W2107986563 @default.
• W2016194112 cites W2108408221 @default.
• W2016194112 cites W2110864471 @default.
• W2016194112 cites W2113517398 @default.
• W2016194112 cites W2123339548 @default.
• W2016194112 cites W2124896191 @default.
• W2016194112 cites W2128683587 @default.
• W2016194112 cites W2148184856 @default.
• W2016194112 cites W2149425953 @default.
• W2016194112 cites W2165291485 @default.
• W2016194112 doi "https://doi.org/10.1038/jid.2011.136" @default.
• W2016194112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21654832" @default.
• W2016194112 hasPublicationYear "2011" @default.
• W2016194112 type Work @default.
• W2016194112 sameAs 2016194112 @default.
• W2016194112 citedByCount "24" @default.
• W2016194112 countsByYear W20161941122012 @default.
• W2016194112 countsByYear W20161941122013 @default.
• W2016194112 countsByYear W20161941122014 @default.
• W2016194112 countsByYear W20161941122015 @default.
• W2016194112 countsByYear W20161941122016 @default.
• W2016194112 countsByYear W20161941122017 @default.
• W2016194112 countsByYear W20161941122018 @default.
• W2016194112 countsByYear W20161941122020 @default.
• W2016194112 countsByYear W20161941122021 @default.
• W2016194112 countsByYear W20161941122022 @default.
• W2016194112 countsByYear W20161941122023 @default.
• W2016194112 crossrefType "journal-article" @default.
• W2016194112 hasAuthorship W2016194112A5011094627 @default.
• W2016194112 hasAuthorship W2016194112A5032742387 @default.
• W2016194112 hasAuthorship W2016194112A5038704848 @default.
• W2016194112 hasAuthorship W2016194112A5043359083 @default.
• W2016194112 hasAuthorship W2016194112A5050880185 @default.
• W2016194112 hasAuthorship W2016194112A5054046984 @default.
• W2016194112 hasAuthorship W2016194112A5073284900 @default.
• W2016194112 hasAuthorship W2016194112A5080570964 @default.
• W2016194112 hasAuthorship W2016194112A5089220498 @default.
• W2016194112 hasAuthorship W2016194112A5090252753 @default.
• W2016194112 hasBestOaLocation W20161941121 @default.
• W2016194112 hasConcept C105696609 @default.
• W2016194112 hasConcept C173396325 @default.
• W2016194112 hasConcept C184235292 @default.
• W2016194112 hasConcept C190283241 @default.
• W2016194112 hasConcept C2777658100 @default.
• W2016194112 hasConcept C29537977 @default.
• W2016194112 hasConcept C502942594 @default.
• W2016194112 hasConcept C54355233 @default.
• W2016194112 hasConcept C57074206 @default.
• W2016194112 hasConcept C62112901 @default.
• W2016194112 hasConcept C84815855 @default.
• W2016194112 hasConcept C86803240 @default.

• next